Published on 16 May 2022 on Zacks via Yahoo Finance
Medtronic's (MDT) Onyx Frontier DES Receives FDA Approval
Medtronic plc MDT announced the receipt of the FDA approval for the Onyx Frontier drug-eluting stent (DES). The Onyx Frontier DES is utilized for treating patients with coronary artery disease (CAD).
The recent FDA approval is likely to fortify Medtronic’s Coronary & Renal Denervation business, which is part of the company’s Cardiovascular portfolio.
For investors’ note, the Onyx Frontier DES is now approved in the United States and is pending the CE Mark.